js_composer domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home3/vacatio2/public_html/medgatetoday/wp-includes/functions.php on line 6260Bringing a new drug to market the traditional way typically takes 10 to 12 years and costs billions of dollars. This is largely due to the complexity of clinical trials, fragmented data systems, and strict regulatory compliance requirements.
To address this gap, TCS has launched ADD AgentHub – a role-based, enterprise-ready Agentic AI platform that allows pharma companies to build their own collection of AI agents and assign them specific roles. These AI agents can independently analyze and execute complex, multi-step workflows, potentially scaling up the entire research and development process significantly.
How Does It Work?
AgentHub is built around what TCS calls a “Human + AI Operating Model.” This means AI agents take on the repetitive, data-heavy parts of a workflow, while humans remain responsible for governance and final decision-making.
Agents on the platform can be used for tasks such as: Clinical data review, Study design and protocol digitisation, Scientific literature analysis, Medical monitoring & Drug safety case processing.
In the tightly regulated pharma industry, every AI action needs to be audit-ready, traceable, and compliant – and TCS says AgentHub has been designed with exactly this requirement in mind.
TCS’s Claims – The Numbers
According to TCS, solutions built on AgentHub have shown significant improvements in the following areas:
| Area | Claimed Improvement |
|---|---|
| Clinical Data Management | Up to 40% efficiency gain |
| Clinical Study Building | Up to 30% lower effort |
| Safety Case Processing | Up to 30% cost savings |
| Quality Control (Safety Agents) | Up to 50% lower effort |
(Note: These figures are company-provided claims and will need to be validated against real-world deployments across different pharma organisations.)
Debashis Ghosh, President of Life Sciences and Healthcare at TCS, said the platform is a role-based, enterprise-ready, and trusted AI solution that will help customers accelerate drug development using agentic AI at scale.
Why Does This Matter?
Agentic AI has become a major focus area for enterprise technology companies – the idea being that software agents can carry out multi-step tasks with minimal manual input. But in the pharma sector, this opportunity comes with tighter constraints, since every AI action may need to be reviewed, logged, and audited.
TCS is clearly targeting this gap with AgentHub, offering a solution that aims to balance innovation with regulatory rigor – potentially helping new medicines reach patients faster than before.
Conclusion
TCS’s launch of ADD AgentHub signals that Agentic AI is no longer just a buzzword – it’s making inroads into real-world, heavily regulated industries like pharma. If these claimed efficiency gains hold up in real-world deployments, drug development timelines could shrink considerably in the coming years, ultimately benefiting patients and the wider healthcare system.
This article is based on publicly available information and company statements. Source: TCS Newsroom and industry reports (17 August 2026).
]]>